Akari Therapeutics Plc (NASDAQ: AKTX ) on Tuesday shared promising preclinical results for its experimental cancer treatment, AKTX-101.
The data highlights the therapy’s potential as a unique option for urothelial cancer, particularly in scenarios where currently available antibody-drug conjugates (ADCs) provide limited clinical benefits.
Addressing Unmet Needs In Oncology
AKTX-101 is a TROP2-directed ADC that leverages a proprietary PH1 RNA spliceosome-modulating payload .
According to the company, this novel mechanism addresses the emerging shortcomings of existing ADC payload categories, such as topoisomerase 1 and microtubule inhibitors.
Latest Private Market Opportunities Join 400,000+ InvestorsUrothelial carcinoma represents a rapidly expanding market for ADC treatments, highlighted by the success of therapies like Padcev.
Despite these advancements, patients who experience a relapse after standard treatments face a severe lack of viable medical options .
Promising Preclinical Tumor Inhibition
During recent evaluations, AKTX-101 displayed meaningful anti-tumor efficacy across various clinically relevant models.
In the UM-UC-14 advanced urothelial carcinoma model—representing a metastatic setting where Padcev is a standard first-line option—AKTX-101 achieved statistically significant tumor growth inhibition, whereas Padcev showed limited effectiveness.
Furthermore, the experimental therapy demonstrated encouraging results against tumors that developed resistance to Trodelvy, a first-generation TROP2-directed ADC. When these resistant tumors were treated with AKTX-101, growth slowed significantly.
This suggests the PH1 payload’s ability to disrupt RNA splicing can overcome resistance linked to traditional Topoisomerase I payloads, potentially offering benefits for lung and breast cancers .
Future Clinical Milestones
Akari continues advancing IND-enabling processes for AKTX-101. The oncology biotechnology firm aims to launch a Phase 1 clinical trial by mid-2027 while simultaneously exploring further development opportunities for its PH1 payload platform to maximize its commercial potential.
AKTX Stock Price Activity: Akari Therapeutics shares were up 2.26% to $7.79 at the time of publication on Tuesday, according to Benzinga Pro data .
Read Next MoversHome Depot Customers Make Fewer Trips but Spend More
Home Depot beats Q2 fiscal 2026 estimates with $47.86B revenue and $4.92 adj EPS, driven by small home improvement projects.
3 min read Read this articlePhoto via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Movers News General Biotech Top Stories Health Care Why It's Moving Retail Investor Stocks